PFS for PET2− and PET2+ patients treated with various schedules of BEACOPP and patients treated on the ECHELON-1 trial continuing on A+AVD and ABVD
| Treatment . | PFS PET2−, % . | PFS PET2+, % . | Conclusion . |
|---|---|---|---|
| • United Kingdom5 • ABVD × 2 − PET2− then ABVD or AVD • ABVD × 2 − PET2+ then BEACOPP-14 or eBEACOPP | 84 | 68 | The conclusion was that this rate was substantially higher than that observed in retrospective series in which patients continued ABVD and is similar to the rates in other series in which patients received BEACOPP |
| • GHSG HD 186 • eBEACOPP − PET2+ then eBEACOPP × 6 or • eBEACOPP × 6 + rituximab | NA | 91.4 | The conclusion was that the PFS of the PET2+ patients was much better than expected |
| 93 | |||
| • GITIL/FIL HD 06077 • ABVD × 2 − PET2− then ABVD ± XRT • ABVD × 2 − PET2+ then eBEACOPP × 4 and standard BEACOPP × 4 ± rituximab | 87 | 60 | The conclusion again is that PET response-adapted treatment is a feasible, safe, and effective therapeutic strategy in advanced HL |
| • SWOG S08168 • ABVD × 2 − PET2− then ABVD × 4 • ABVD × 2 − PET2+ then eBEACOPP × 6 | 76 | 66 | The conclusion was that, in PET2+ patients who received eBEACOPP, PFS was favorable but was associated with a high rate of second malignancies; there was 24% progression in PET2− at 5 y |
| • ECHELON-11 : ABVD × 2 − PET2 ± ABVD × 4 | 79.5 | 51.5 | A+AVD provides durable efficacy benefit regardless of patient status at PET2 |
| • ECHELON-1: A+AVD × 2 PET2 ± A+AVD × 4 | 85.8 | 67.7 |
| Treatment . | PFS PET2−, % . | PFS PET2+, % . | Conclusion . |
|---|---|---|---|
| • United Kingdom5 • ABVD × 2 − PET2− then ABVD or AVD • ABVD × 2 − PET2+ then BEACOPP-14 or eBEACOPP | 84 | 68 | The conclusion was that this rate was substantially higher than that observed in retrospective series in which patients continued ABVD and is similar to the rates in other series in which patients received BEACOPP |
| • GHSG HD 186 • eBEACOPP − PET2+ then eBEACOPP × 6 or • eBEACOPP × 6 + rituximab | NA | 91.4 | The conclusion was that the PFS of the PET2+ patients was much better than expected |
| 93 | |||
| • GITIL/FIL HD 06077 • ABVD × 2 − PET2− then ABVD ± XRT • ABVD × 2 − PET2+ then eBEACOPP × 4 and standard BEACOPP × 4 ± rituximab | 87 | 60 | The conclusion again is that PET response-adapted treatment is a feasible, safe, and effective therapeutic strategy in advanced HL |
| • SWOG S08168 • ABVD × 2 − PET2− then ABVD × 4 • ABVD × 2 − PET2+ then eBEACOPP × 6 | 76 | 66 | The conclusion was that, in PET2+ patients who received eBEACOPP, PFS was favorable but was associated with a high rate of second malignancies; there was 24% progression in PET2− at 5 y |
| • ECHELON-11 : ABVD × 2 − PET2 ± ABVD × 4 | 79.5 | 51.5 | A+AVD provides durable efficacy benefit regardless of patient status at PET2 |
| • ECHELON-1: A+AVD × 2 PET2 ± A+AVD × 4 | 85.8 | 67.7 |
A, brentuximab vedotin; AVD, doxorubicin, vinblastine, and dacarbazine; BEACOPP-14, standard dose BEACOPP every 14 days; GHSG HD, German Hodgkin Study Group HD9 study; GITIL/FIL HD, Gruppo Italiano Terapie Innovative nel Linfomi/Fondazione Italiana Linfomi HD study; NA, not applicable; XRT, radiation.